Stamakort®
Biologically active food supplement STAMAKORT® contains a complex of low molecular weight pep-
tides with a molecular weight of up to 5000 Da, isolated from the gastric mucosa tissues of young
animals - calves up to 12 months of age or pigs.
STAMAKORT® is available in capsules with an active substance content of 10 mg.
STAMAKORT® peptides regulate metabolic processes in the gastric mucosa cells, increase the reserve
capacity of the gastrointestinal tract, have a beneficial effect on the adaptation processes of the body
in extreme conditions, have antioxidant properties, and regulate the processes of peroxidation in the
tissues of the gastric mucosa. Experimental studies have shown that peptides have a tissue-specific
effect on the cells of those tissues from which they are isolated. This allows us to assume the effec-
tiveness of the use of STAMAKORT® to restore the functions of the gastrointestinal tract with dis-
orders of various origins.
Chronic inflammatory diseases of the stomach and duodenum and postoperative complications are
the cause of the formation of functional insufficiency and disorders of the secretory and motor func-
tions of various parts of the gastrointestinal tract (1, 2, 3), which significantly reduce the quality of life
of people of different ages.
Medical treatment of these diseases includes the use of the following drugs (2, 3):
- Enzyme drugs that improve digestion (pepsin, panzinorm, mezim-forte, festal);
- Bitters (centaury grass, wormwood herb, dandelion root);
- Ganglion blockers (hexonium, metacin);
- Multivitamins;
- Biostimulants (aloe);
- etc.
The clinical study of STAMAKORT® was carried out at the Medical Center of the St. Petersburg In-
stitute of Bioregulation and Gerontology from February to August 2011.
In clinical trials of STAMAKORT®, 47 patients with chronic gastritis took part, who complained of a
feeling of heaviness and fullness in the epigastric region, bloating, belching with food or air, rumbling
in the abdominal cavity, stool disturbance, and general weakness. At times the patients were disturbed
by a dull, aching pain in the epigastric region after eating. The distribution of patients by sex and age
is shown in Table 1.
All patients previously received symptomatic and pathogenetic therapy for these diseases.
The patients were randomized into 2 groups. The control group included 17 patients who received
conventional therapy.
In addition to conventional therapy, patients of the primary group (30 people) received STAMAKORT®
orally 10-15 minutes before meals, 1-2 capsules 3 times a day for 30 days, depending on the severity
of the pathological process.
Distribution of patients by sex and age. Table 1
Diagnosis Age Group Male Female Total
Chronic gastritis with secretory 36-72 Control 10 7 17
insufficiency
35-70 Primary 19 11 30
Total: 29 18 47
RESEARCH METHODS
The patients’ complaints were assessed in dynamics, a general clinical examination of blood and urine,
and a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany)
were carried out. Determination of the secretory function of the stomach and fibrogastroscopywere
carried out as well.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.